Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Bertoldo

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Bone|November 10, 2023
Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide databaseGiovanni Adami, Davide Gatti, Maurizio Rossini, et al.
Oncotarget|November 2, 2017
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundationLuisella Cianferotti, Francesco Bertoldo, Marco Carini, et al.
The Lancet. Oncology|May 21, 2013
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trialDino Amadori, Massimo Aglietta, Barbara Alessi, et al.
Oral Diseases|February 6, 2024
Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)Alberto Bedogni, Rodolfo Mauceri, Vittorio Fusco, et al.
JCO Oncology Practice|February 13, 2020
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline SummaryVittorio Fusco, Daniele Santini, Giuseppina Campisi, et al.
Arthritis Research & Therapy|August 27, 2010
The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulationMaria Teresa Valenti, Sandro Giannini, Luca Donatelli, et al.
Calcified Tissue International|October 24, 2008
Intramuscular neridronate in postmenopausal women with low bone mineral densitySilvano Adami, Davide Gatti, Francesco Bertoldo, et al.
The Journal of Clinical Endocrinology and Metabolism|November 9, 2004
Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptorAlfredo Scillitani, Vito Guarnieri, Simona De Geronimo, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
The International Journal of Eating Disorders|June 9, 2017
Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosaAlessandro Giollo, Luca Idolazzi, Cristian Caimmi, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Bone|November 10, 2023
Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide databaseGiovanni Adami, Davide Gatti, Maurizio Rossini, et al.
Oncotarget|November 2, 2017
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundationLuisella Cianferotti, Francesco Bertoldo, Marco Carini, et al.
The Lancet. Oncology|May 21, 2013
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trialDino Amadori, Massimo Aglietta, Barbara Alessi, et al.
Oral Diseases|February 6, 2024
Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)Alberto Bedogni, Rodolfo Mauceri, Vittorio Fusco, et al.
JCO Oncology Practice|February 13, 2020
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline SummaryVittorio Fusco, Daniele Santini, Giuseppina Campisi, et al.
Arthritis Research & Therapy|August 27, 2010
The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulationMaria Teresa Valenti, Sandro Giannini, Luca Donatelli, et al.
Calcified Tissue International|October 24, 2008
Intramuscular neridronate in postmenopausal women with low bone mineral densitySilvano Adami, Davide Gatti, Francesco Bertoldo, et al.
The Journal of Clinical Endocrinology and Metabolism|November 9, 2004
Blood ionized calcium is associated with clustered polymorphisms in the carboxyl-terminal tail of the calcium-sensing receptorAlfredo Scillitani, Vito Guarnieri, Simona De Geronimo, et al.
JBMR Plus|November 11, 2021
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment GoalsFelicia Cosman, Cesar Libanati, Cynthia Deignan, et al.
The International Journal of Eating Disorders|June 9, 2017
Vitamin D levels strongly influence bone mineral density and bone turnover markers during weight gain in female patients with anorexia nervosaAlessandro Giollo, Luca Idolazzi, Cristian Caimmi, et al.
Pageof 8